TSENTROKUIN table. 100 mg

TSENTROKUIN table. 100 mg
€ 17.00
Add to Cart
Your medicine is called Tsentrokuin and a tablet containing 100 mg of quetiapine hemifumarate as the active ingredient. Tsentokuin is indicated for the treatment of schizophrenia and the treatment of moderate to severe manic episodes. Tsentrokuin not prevent recurrence of manic episodes associated with bipolar disorder. No data available for bipolar disorder after 8 weeks.

TSENTROKUIN table. 100 mg
 

TSENTROKUIN WHAT IS AND WHAT IT IS USED

Your medicine is called Tsentrokuin and a tablet containing 100 mg of quetiapine hemifumarate as the active ingredient. Tsentokuin is indicated for the treatment of schizophrenia and the treatment of moderate to severe manic episodes. Tsentrokuin not prevent recurrence of manic episodes associated with bipolar disorder. No data available for bipolar disorder after 8 weeks.
 

BEFORE YOU TAKE TSENTROKUIN

 
Do not take Tsentrokuin
  If you are allergic to quetiapine or any of the other ingredients of Tsentrokuin
  If you are taking medicines, such as HIV-protease inhibitors, azole antifungals, erythromycin, clarithromycin and nefazodone.
 
Take special care with Tsentrokuin
 
 When you have known cardiovascular disease, cerebrovascular disease or other conditions, prerazpolagashti to hypotension. Quetiapine may induce orthostatic hypotension, especially during the initial period of dose escalation and therefore must assess the need for dose reduction or dose titration if this happens
  If you have liver disease
  In the treatment of patients with a history of seizures
  If signs or symptoms of tardive dyskinesia. In this case you should consider dose reduction or discontinuation of Tsentokuin.
 
The occurrence of nevrolieptichen malignant syndrome. Clinical manifestations include hyperthermia, altered mental status, muscle rigidity, autonomic instability, and increased creatine phosphokinase. In this case Tsentrokuin should be discontinued and appropriate therapy initiated.
 
Pregnancy and lactation
 
Ask your doctor or pharmacist before taking any medicine. During pregnancy Tsentrokuin should be used only if the benefit justifies the potential risk. Following pregnancies in which it is applied Tsentrokuin observed neonatal withdrawal symptoms. The rate of excretion of quetiapine in breast milk is unknown. Therefore, women who are breastfeeding should be advised to avoid breast-feeding while taking Tsentrokuin.
 
Driving and operating machinery
 
Given the primary central nervous system Tsentrokuin may interfere with activities requiring mental concentration. Therefore, patients should be advised not to drive or operate machinery, until individual susceptibility.
 

HOW TO TAKE TSENTROKUIN

 
Always Tsentrokuin exactly as you told your doctor. If you're not sure, ask your doctor
 
Adults:
 
Schizophrenia Tsentrokuin should be taken twice daily. The total daily dose for the first four days of therapy is 50 mg / day 1/100 mg / day 2/200 mg / day 3/300 mg / day 4 /. After the fourth day onwards, the recommended dose is 300 to 450 mg. It can be adjusted according to clinical response and tolerability of the individual patient ranged from 150 to 750 mg daily.
 
For the treatment of naniyni episodes associated with bipolyano razstoystvo Tsentrokuin should be taken twice daily. The total daily dose for the first four days of treatment was 100 mg / day 1/200 mg / day 2/300 mg / day 3 / and 400 mg / day 4 /. Further dosage adjustments up to 800 mg daily until the sixth day should be done by increasing the dose to 200 mg per day. The dose may be adjusted depending on clinical response and tolerability of the individual patient ranged from 200 to 800 mg per day. The usual effective dose is in the range of 400 to 800 mg per day.
  
Elderly
 
As with other antipsychotics, Tsentrokuin should be used with caution in elderly patients especially during the initial dosing period. The frequency of dose titration of Tsentrokuin may need to be slower and teratevtichna daily dose was lower than in younger patients. The mean plasma clearance of quetiapine was reduced by 30% -50% in elderly compared with younger patients.
Children and adolescents: 
The safety and effectiveness of Tsentrokuin in children and adolescents has not been assessed.
Renal impairment 
No dosage adjustment for patients with renal impairment
Hepatic impairment:
 
Quetiapine is extensively metabolized by the liver. Tsentrokuin therefore should be used with caution in patients with known hepatic impairment should be started at 25 mg daily. The dose should be increased by 25 to 50 mg per day until an effective dose, depending on clinical response and tolerability of the individual patient.
 

POSSIBLE SIDE EFFECTS

 
The most common side effects with Tsentrokuin are somnolence, dizziness, dry mouth, mild asthenia, constipation, tachycardia, orthostatic hypotension and dyspepsia.
 

 Side Effects:

 
Very common - dizziness, somnolence, headache
 
Common - shortness of breath, dry mouth, constipation, dyspepsia, weight gain, mild asthenia, peripheral edema, nasal congestion, malaise
 
Uncommon - hypersensitivity, convulsions, increased total cholesterol
 
Rare - fever, lethargy, a marked increase in blood pressure and heart rate, jaundice, priapism, neuroleptic malignant syndrome
 
Very rare - high blood sugar, hepatitis, angioedema syndrome, Stevens-Johnson
 

What Tsentrokuin:

 
The active substance is quetiapine hemifumarate
The other ingredients are lactose monohydrate, etc..
€ 17.00
Add to Cart
Close